You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

BEPREVE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Bepreve patents expire, and what generic alternatives are available?

Bepreve is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has eleven patent family members in eight countries.

The generic ingredient in BEPREVE is bepotastine besilate. There are seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bepotastine besilate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Bepreve

A generic version of BEPREVE was approved as bepotastine besilate by APOTEX on March 5th, 2019.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for BEPREVE?
  • What are the global sales for BEPREVE?
  • What is Average Wholesale Price for BEPREVE?
Drug patent expirations by year for BEPREVE
Drug Prices for BEPREVE

See drug prices for BEPREVE

Recent Clinical Trials for BEPREVE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Southern California College of OptometryPhase 4
Southern California College of Optometry at Marshall B. Ketchum UniversityPhase 4
McCabe Vision CenterN/A

See all BEPREVE clinical trials

Pharmacology for BEPREVE
Paragraph IV (Patent) Challenges for BEPREVE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
BEPREVE Ophthalmic Solution bepotastine besilate 1.5% 022288 3 2013-09-09

US Patents and Regulatory Information for BEPREVE

BEPREVE is protected by one US patents.

Patents protecting BEPREVE

Aqueous liquid preparations and light-stabilized aqueous liquid preparations
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc BEPREVE bepotastine besilate SOLUTION/DROPS;OPHTHALMIC 022288-001 Sep 8, 2009 AT RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BEPREVE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb Inc BEPREVE bepotastine besilate SOLUTION/DROPS;OPHTHALMIC 022288-001 Sep 8, 2009 ⤷  Sign Up ⤷  Sign Up
Bausch And Lomb Inc BEPREVE bepotastine besilate SOLUTION/DROPS;OPHTHALMIC 022288-001 Sep 8, 2009 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for BEPREVE

See the table below for patents covering BEPREVE around the world.

Country Patent Number Title Estimated Expiration
Hong Kong 1022477 ⤷  Sign Up
Japan 5518928 ⤷  Sign Up
Taiwan 486475 ⤷  Sign Up
Japan 2012180360 ACID ADDITION SALT OF OPTICALLY ACTIVE PIPERIDINE DERIVATIVE, AND METHOD FOR PRODUCING THE SAME ⤷  Sign Up
Australia 2003252746 AQUEOUS LIQUID PREPARATIONS AND LIGHT-STABILIZED AQUEOUS LIQUID PREPARATIONS ⤷  Sign Up
South Korea 101016595 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.